{"id":"W2101922439","doi":"10.1016/s1470-2045(14)70379-1","title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":1019,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Merck KGaA","keywords":"Temozolomide; Medicine; Chemoradiotherapy; Internal medicine; Oncology; Clinical endpoint; Phases of clinical research; Progression-free survival; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001130289,0.001782487,0.003503492,0.0005193014,0.0003790272,0.00110101,0.001091098,0.001831337,0.005201884],"category_scores_gemma":[0.001114259,0.0006250493,0.002240949,0.0005650118,0.001162942,0.001325924,0.000421594,0.003533505,0.001176138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001046928,"about_ca_system_score_gemma":0.0009761634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002050369,"about_ca_topic_score_gemma":0.005602174,"domain_scores_codex":[0.9996365,0.0001578988,0.00001535498,0.00007779164,0.00002650225,0.00008599294],"domain_scores_gemma":[0.9995667,0.0001047696,0.00008374877,0.0000353784,0.00002869936,0.0001806756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9714835,0.00326861,0.000654049,0.000798471,0.001416544,0.00004641497,0.00004863319,0.0004560852,0.001858758,0.000166483,0.002031298,0.01777118],"study_design_scores_gemma":[0.9486884,0.04710636,0.001976666,0.00004823815,0.0006028507,0.00003279429,0.00003386041,0.0003469911,0.0001963249,0.0002028264,0.0007456295,0.00001892147],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814263,0.009244174,0.0006676135,0.001382723,0.001123554,0.001749939,0.001548238,0.0001936491,0.002663754],"genre_scores_gemma":[0.9820936,0.005045438,0.001371364,0.001981345,0.0005969268,0.002048497,0.002611091,0.00004268125,0.004208999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005201884,"threshold_uncertainty_score":0.01740199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04591526199650049,"score_gpt":0.3746563513188675,"score_spread":0.3287410893223671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}